Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Lindsay E CleggHiddo J Lambers HeerspinkRobert C PenlandWeifeng TangDavid W BoultonSrinivas BachinaRobert D FoxPeter FeniciMarcus ThuressonRobert J MentzAdrian F HernandezRury R HolmanPublished in: Diabetes care (2018)
This post hoc analysis of the placebo arm of EXSCEL supports a beneficial class effect for all SGLT2i, including dapagliflozin, for reduced ACM and less eGFR decline.